Kvit K. B.

ZONULIN LEVEL AS A RISK FACTOR FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH DYSLIPIDEMIA

---

Show/Download

About the author:

Kvit K. B.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia are among the most common metabolic disorders in the world today. There is evidence that increased intestinal permeability is associated with insulin resistance, which is one of the key factors in the development of lipid metabolism disorders and NAFLD. According to some researchers, zonulin increasing (the marker of increased intestinal permeability) may correlate with the progression of this condition and cause further complications. Also, according to some studies, there may be a relationship between the small intestinal bacterial overgrowth (SIBO) in the intestine and lipid metabolism disorders due to the influence of endotoxins. We examined 342 patients with dyslipidemia, of whom 152 were diagnosed with NAFLD. When determining the frequency of SIBO in the group with dyslipidemia, it was 45%, in the group with NAFLD – 53.2%. The level of fecal zonulin in the group with dyslipidemia did not exceed the upper limit of normal and was 87±0.28 nm/g, in the group with NAFLD – 115±2.76 ng/g, which is significantly higher than normal (n=107 ng/g). The correlations between zonulin and high-sensitivity C-reactive protein and triglycerides as markers of cardiometabolic risk in the group of patients with NAFLD and a negative correlation between the presence of SIBO and HDL-C levels in patients with dyslipidemia were established. Determination and correction of fecal zonulin and treatment of excessive bacterial growth in the gut may be important approaches in the prevention and treatment of NAFLD and metabolic disorders.

Tags:

Bibliography:

1. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691-1705.
2. Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed). 2021;26(2):206-237
3. Manzhaliy EG. Zhyrova khvoroba pechinky. Nova nomenklatura. Suchasna hastroenterolohiya. 2023;4:91-9. [in Ukrainian].
4. Kvit KB, Kharchenko NV. Gut microbiota changes as a risk factor for obesity. Wiad Lek. 2017;70(2):231-235.
5. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015;42(9):1051-63.
6. Hendy OM, Elsabaawy MM, Aref MM, Khalaf FM, Oda AMA, El Shazly HM. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. APMIS. 2017;125(7):607-613.
7. Carpino G, Del Ben M, Pastori D, Carnevale R, Baratta F, Overi D, et al. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology. 2020;72(2):470-485
8. Kvit KB, Kharchenko NV, Kharchenko VV, Chornenka OI, Chornovus RI, Dorofeeva US, et al. The role of small intestinal bacterial overgrowth in the pathogenesis of hyperlipidemia. Wiad Lek. 2019;72(4):645-649.
9. Didyk OI, Cherniavskyi V. Koreliatsiini zviazky mizh rivnem zonulinu, leptynu ta antropometrychnymy pokaznykamy u patsientiv z metabolychno-asotsiiovanoyu zhyrovoyu khvoroboyu pechinky u poiednanni z tsukrovym diabetom 2-ho typu. Simeina Medytsyna. Yevropeiski praktyky. 2023;3:50-54. [in Ukrainian].
10. Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020;319(6):H1227-H1233
11. Dmytriv TR, Storey KB, Lushchak VI. Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise. Front Physiol. 2024;15:1380713
12. Didyk OK, Cherniavskyi VV. Vzaiemozviazok mizh kontsentratsiieiu zonulinu ta pokaznykamy lipidnoho obminu v patsientiv iz metabolichnoasotsiiovanoyu zhyrovoyu khvoroboyu pechinky u poiednanni z tsukrovym diabetom 2 typu. Suchasna hastroenterolohiya. 2023;5:5-9. [in Ukrainian].
13. Rosso C, Caviglia GP, Armandi A, Ribaldone DG, Bugianesi E. Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease? Clin Res Hepatol Gastroenterol. 2021;45(2):101611
14. Seethaler B, Basrai M, Neyrinck AM, Nazare JA, Walter J, Delzenne NM, et al. Biomarkers for assessment of intestinal permeability in clinical practice. Am J Physiol Gastrointest Liver Physiol. 2021;321(1):G11-G17.
15. Parkhomenko LK, Strashok LA, Khomenko MA. The role of zonulin in the development of liver fibrosis in obese adolescents. Wiad Lek. 2021;74(1):77-82.
16. Solomentseva TA. Novi kryterii metabolichno-asotsiiovanoyi zhyrovoyi khvoroby pechinky: perevaha chy pytannia? Ohliad. Suchasna hastroenterolohiya. 2023;4:84-90. [in Ukrainian].

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 3, 174, 140-149 pages, index UDC 616.36-003.826+616.153.915)] - 07 – 038 : 577.112

DOI:

10.29254/2077-4214-2024-3-174-140-149